Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome

Biol Psychiatry. 1992 Nov 1;32(9):834-8. doi: 10.1016/0006-3223(92)90087-g.

Abstract

Chronic fatigue syndrome (CFS) includes many symptoms of major depression. For this reason, many antidepressants have been used to treat the symptoms of this disorder. Among the more recently released antidepressants are fluoxetine and bupropion. In this open study, nine CFS patients who either could not tolerate or did not respond to fluoxetine showed significant response when administered 300 mg/day of bupropion for an 8-week period in both rating of HDRS (t = 4.80, p < 0.01) and BDI (t = 2.48, p < 0.05). Furthermore, bupropion improvement in Hamilton Depression Rating Scale correlated significantly with change in plasma homovanillic acid (HVA) (r = 0.96, p < 0.01). Plasma total methylhydroxyphenolglycol (MHPG) also increased significantly during bupropion treatment (t = 2.37, p = 0.05). Measures of T1 microsomal antibodies also decreased over treatment time; increases in natural killer cell numbers correlated inversely with change in plasma levels of free MHPG (r = -0.88, p < 0.05). Bupropion responders were more likely to have trough blood levels above 30 ng/ml (chi 2 = 3.6, p = 0.05).

MeSH terms

  • Adult
  • Bupropion / administration & dosage*
  • Depressive Disorder / drug therapy
  • Depressive Disorder / psychology
  • Fatigue Syndrome, Chronic / drug therapy*
  • Fatigue Syndrome, Chronic / psychology
  • Female
  • Fluoxetine / administration & dosage*
  • Follow-Up Studies
  • Homovanillic Acid / blood
  • Humans
  • Immunity, Cellular / drug effects
  • Male
  • Methoxyhydroxyphenylglycol / blood
  • Middle Aged
  • Personality Inventory

Substances

  • Fluoxetine
  • Bupropion
  • Methoxyhydroxyphenylglycol
  • Homovanillic Acid